Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study

We performed a retrospective study to compare the hematologic response, organ response, and overall survival in patients with light chain amyloidosis, receiving bortezomib-based therapy before autologous stem cell transplantation (ASCT) versus non –bortezomib-based therapy or no therapy before ASCT. In the present study, although the patients who received bortezomib before transplantation were at greater risk at baseline, we found significantly better outcomes in these patients.

Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2018 Category: Hematology Authors: Tania Jain, Heidi E. Kosiorek, Shu T. Kung, Vishal S. Shah, Amylou C. Dueck, Veronica Gonzalez-Calle, Susan Luft, Craig B. Reeder, Roberta Adams, Pierre Noel, Jeremy T. Larsen, Joseph Mikhael, Leif Bergsagel, A. Keith Stewart, Rafael Fonseca Tags: Original Study Source Type: research